Active Ingredient(s): Pimavanserin
FDA Approved: * April 29, 2016
Category: Antipsychotic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nuplazid Overview

Pimavanserin (ACP-103; BVF-036), sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being researched for the treatment of Alzheimer’s disease psychosis, schizophrenia, agitation, and major depressive disorder.[3] Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist.[4] Contents 1 Pharmacology 1.1 Pharmacodynamics 2 History 2.1 De...

Read more Nuplazid Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nuplazid Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 34mg
  • Tablet: 10mg, 17mg
  • Unknown: Unknown
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nuplazid: (3 results)

Sorted by National Drug Code
  • 63090-100 Nuplazid 10 mg Oral Tablet, Coated by Acadia Pharmaceuticals Inc
  • 63090-170 Nuplazid 17 mg Oral Tablet, Coated by Acadia Pharmaceuticals Inc
  • 63090-340 Nuplazid 34 mg Oral Capsule by Acadia Pharmaceuticals Inc

Other drugs which contain Pimavanserin or a similar ingredient: (1 result)